We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug News
    • Trending
    • Commercial Operations
    • GMPs
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Drug Weekly
    • FDAnews
  • Device News
    • Trending
    • Commercial Operations
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Device Weekly
    • FDAnews
  • Books
    • FDAnews Books Library
    • Drug Books
    • Device Books
  • Training/Events
    • Webinar Training Pass
    • Events
    • Webinar Recordings
  • Resources
    • Form 483s Database
    • FDA Approved Drugs
  • CenterWatch
  • About Us
    • The Company
    • FDAnews Editorial Board
    • Contact Us
  • Advertising
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » A Quality Management Journey: How to Avoid Repeat CAPAs

A Quality Management Journey: How to Avoid Repeat CAPAs

May 20, 2016

Having a risk tool to determine what situations require corrective and preventive actions is one strategy devicemakers can use to avoid repeat CAPAs.

In fact, one expert suggested the CAPA process is designed as an opportunity to respond to critical and systemic issues, investigate them, and resolve them to mitigate the risk of recurrence.

However, many companies are doing the process incorrectly, said Alexandre Alain, a lifescience product manager at VERSE Solutions during an FDAnews webinar.

Alain identified some of the reasons for repeat CAPAs, including poor investigations and root cause analysis. If a devicemaker can’t identify the correct cause of an issue, it will fix the wrong problem. Along those lines, companies don’t do the legwork to develop the right solution to correct a problem.

Don’t Forget Effectiveness Check

Not having an effectiveness check is another leading cause of a repeat CAPA, Alain said, adding that inadequate training of personnel, poor use of data, lack of a risk assessment also lands companies in hot water.

One way to help prevent these recurrences is the creation of a risk table that documents complaints, reports of nonconformance or other events. These tables can include information on severity, frequency or any preassigned risk elements.

Based on that risk table, “the event can either be immediately corrected within the process or put into a critical event and investigated more thoroughly to see, moving forward, if the CAPA is needed,” he added.

Training and qualification are also key factors to consider. “Do not think anyone can do a CAPA,” he said, adding that it is essential to have the correct personnel in place who understand what is going on. Don’t rely on one person doing everything — rather, ensure that there are people with the knowledge and skills to tackle the various steps of the CAPA process.

Deciding When a CAPA Is Needed

The next step is defining whether a CAPA and investigation are warranted. It is crucial at this stage to fully understand and define the problem so others may avoid it in the future. To that end, company personnel should write out the problem description thoroughly.

However, the people documenting the problem are not always the ones who will establish an action plan and conduct the investigation, “so a good problem description is crucial,” Alain said.

With that said, a problem description should not contain too much extraneous information — having a clear summary should be the goal.

Full Disclosure

Alain also urged that the description of the problem be truthful, as hiding issues from the management or auditors will prevent companies from effectively tackling the problem.

The next step is the investigation and root cause analysis. The investigation should involve team members from multiple departments to help document information and question personnel to demonstrate the company did its due diligence.

Companies also should become proficient at using root cause analysis techniques to address specific problems. Alain noted there are many techniques, such as the cause-and-effect diagram and Pareto charting, and it’s imperative to build internal expertise so personnel can identify root causes easily.

In addition, companies should be aware that there could be multiple root causes that go beyond “operator error” and “lack of training.”

Finally, create CAPAs that are deliverable, resisting the urge to rush just to finish them. “Do not focus on due date, but more on correcting the issue,” he advised.

Quality

    Upcoming Events

    • 07Dec

      Proactive Supplier Management Using Quality Agreements

    • 13Dec

      FDA Inspection Overhaul: How Things Have Changed in 2023

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • FDA, FTC and DOJ Enforcement of Medical Device Regulations

      FDA, FTC and DOJ Enforcement of Medical Device Regulations

    • Using Real-World Evidence in Drug and Device Submissions

      Using Real-World Evidence in Drug and Device Submissions

    Featured Stories

    • FDA Laboratory-Developed Tests Proposal Comments Pour In by Thousands

    • Healthcare Titans Expand Their Portfolios in Acquisition Deals

    • Ups and Downs of Gene Therapy Weighed by FDA’s Marks

    • Device Manufacturers Pressed by Europe’s MDCG to Get Certified ASAP

    The Revised ICH E8: A Guide to New Clinical Trial Requirements

    Learn More
    • Drug Products
      • Quality
      • Regulatory Affairs
      • GMPs
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Device Products
      • Quality
      • Regulatory Affairs
      • QSR
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Clinical Products
      • Trial Design
      • Data Integrity
      • GCP
      • Inspections and Audits
      • Transparency
    • Privacy Policy
    • Do Not Sell or Share My Data
    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing